SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
Meridian Medical Technologies, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
COMMON STOCK, $.010 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
589658103
- --------------------------------------------------------------------------------
(CUSIP Number)
Robert G. Foster, 4 Milk Street, Portland, ME 04101
- --------------------------------------------------------------------------------
(Name, Address, Telephone Number of Persons Authorized to Receive Notices and
Communications)
April 5, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
Page 1 of Pages
<PAGE>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON
Bioventures Partners Limited Partnership
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS [ ]
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
- --------------------------------------------------------------------------------
NUMBER OF SHARES 7 SOLE VOTING POWER
BENEFICIALLY OWNED BY EACH
REPORTING PERSON WITH 0
------------------------------------------------
8 SHARED VOTING POWER
439,947
------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
------------------------------------------------
10 SHARED DISPOSITIVE POWER
439,947
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
439,947*
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.69%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN* Beneficial ownership expressly disclaimed.
- --------------------------------------------------------------------------------
<PAGE>
ITEM 1. SECURITY AND ISSUER. The class of securities to which this Schedule
relates is Common Stock, $.10 par value of Meridian Medical Technologies, Inc.,
a Delaware corporation (the "Issuer"). The address of the principal executive
office of the Issuer is:
Meridian Medical Technologies, Inc.
10240 Old Columbia Road
Columbia, Maryland 21046
ITEM 2. IDENTITY AND BACKGROUND.
(a) The reporting person's name is BioVenture Partners Limited Partnership, a
Delaware limited partnership with a principal business and office address of 4
Milk Street, Portland, ME 04101. The reporting person's principal business is
that of manager of two venture capital funds, Commonwealth BioVentures IV
Limited Partnership ("Fund IV") and Commonwealth BioVentures V Limited
Partnership ("Fund V").
During the last five years, the reporting person has not been
convicted in a criminal proceeding (excluding traffic violations and similar
misdemeanors). During the last five years, the reporting person has not been a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding has been or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. This item is not
applicable to the reporting person.
ITEM 4. PURPOSE OF TRANSACTION. This item is not applicable to the reporting
person.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) The number of securities of the Issuer the reporting person may be
deemed to beneficially own is 439,947. Of those, 162,756 represent securities
which the reporting person may be deemed to have the right to acquire within 60
days. This aggregate represents approximately 14.69% of the Issuer's outstanding
class of such securities. The reporting person expressly disclaims beneficial
ownership of all securities reported in this Schedule.
(b) The reporting person does not have the sole power to vote and the sole
power to dispose of any of the shares of the Issuer's securities. By virtue of
its position as general partner, the reporting person may be deemed to share the
power to vote and the power to dispose of the following common stock of the
Issuer with the entities so indicated: (i) 120,382 shares with Fund
<PAGE>
IV and (ii) 319,565 shares with Fund V. However, the reporting person expressly
disclaims beneficial ownership of these shares. The business address of Fund IV
and V is 4 Milk Street, Portland, ME 04101. Fund IV and V are venture capital
funds. Within the last five years, neither Fund IV or V has been convicted in a
criminal proceeding (excluding traffic violations and similar misdemeanors) or
has been a party to a civil proceeding of a judicial administrative body of
competent jurisdiction and as a result of such proceeding has been or is subject
to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state securities laws
or finding any violation with respect to such laws.
(c) Fund IV sold 20,000 shares of the Issuer's Common Stock in a public
sale between April 5, 1999 and April 19, 1999. Specifically, Fund IV sold 100
shares on April 5, 1999 at $5.25 per share; 3,700 shares on April 6, 1999 at
$5.00 per share; 3,000 shares on April 9, 1999 at $4.50 per share; 8,200 shares
on April 15, 1999 at $4.0076 per share; 2,000 shares on April 16, 1999 at $4.00
per share; and 3,000 shares on April 19, 1999 at $4.00 per share.
Fund V sold 20,000 shares of the Issuer's Common Stock in a public
sale between April 12, 1999 and April 19, 1999. Specifically, Fund V sold 3,300
shares on April 12, 1999 at $4.125 per share; 10,000 shares on April 14, 1999 at
$4.00 per share; and 6,700 shares on April 19, 1999 at $4.00 per share.
(d) Not Applicable.
(e) Not Applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER. This item is not applicable to the reporting person.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. This item is not applicable to the
reporting person.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete, and correct.
BIOVENTURE PARTNERS
LIMITED PARTNERSHIP
By: Commonwealth BioVentures, Inc. its
general partner
5/14/99 By: /s/ Robert G. Foster
--------------------- ------------------------------------
Date Robert G. Foster, President
